ASMQ to treat Malaria

Fixed dose combination of Artesunate + Mefloquine
First new malaria treatment made in Latin America,
for Latin America, South East Asia and Africa!
  • Launched in 2008.
  • Included in the Essential Medicines List (EML) and Essential Medicines List for children (EMLc) of the WHO in 2013.
  • Developed by an innovative collaboration between DNDi, Brazil and South-East Asia within the FACT Project Consortium.
  • Produced by Farmanguinhos/Fiocruz (Brazilian public pharmaceutical company).
  • The 2-in-1 combination ensures that both drugs are taken together in correct proportions.
  • Simple and Adapted Regimen for Children and Adults. As Easy as 1-2-3!
  • Adapted Packaging: 3 years shelf life: the longest shelf life of any FDC for malaria.
  • High compliance and low risk of resistance.
  • WHO Prequalification in September 2012.
  • February 2013: Case Study on the story of artesunate–mefloquine (ASMQ), on innovative partnerships in this collaborative approach to drug development involving international partnerships and independent funding mechanisms and how it is a powerful way to develop drugs for tropical diseases.
  • Registered in Brazil in 2008, in India in 2011, in Malaysia and Myanmar in 2012; in Tanzania in 2013; in Vietnam, Niger and Burkina Faso in 2014; in Thailand and Cambodia in 2015 and Cameroon in 2016.
  • Successful South-South technology transfer from Farmanguinhos to Cipla Ltd, India.
  • Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs.
  • Soon available in other countries in Latin America, Southeast Asia and Africa.
  • Handed over to the MMV Access and Product Management team in May 2015 to help maximize patient access – read statement.

 

ASMQ brochure, September 2012
ASMQ scientific document, September 2012
ASMQ press pack, April 2008

 


Read more about ASMQ project

 

 ASMQ News
Implementation progress

Handed over to MMV Access team

ASMQ: registered in Cameroon!

Farmanguinhos/Fiocruz admitted to PAHO Strategic Fund

830’000 treatments distributed

Recent Scientific Publications

Journal of Antimicrobial Chemotherapy, June 2014

Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso
Malaria Journal, May 2014
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria
Malaria Journal, December 2013
Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India